Ptcb Quiz: Rems Requirements
20 questions · exam conditions
0:00
Rems RequirementsQuestion 1 of 20

The Transmucosal Immediate-Release Fentanyl (TIRF) REMS program is designed to mitigate the risk of misuse, abuse, and overdose. A key element of this program is:

limiting its use to patients who are opioid-tolerant.
requiring the medication to be dispensed in a child-resistant blister pack.
mandating co-prescription of naloxone with every fill.
restricting dispensing to hospital outpatient pharmacies only.
← Back to quizzes

Ptcb Quiz

Ptcb Quiz: Rems Requirements

Practice Rems Requirements in Ptcb with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Rems Requirements, giving you a quick way to practice the rules, question types, and explanations that matter most for Ptcb.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

The Transmucosal Immediate-Release Fentanyl (TIRF) REMS program is designed to mitigate the risk of misuse, abuse, and overdose. A key element of this program is:

  1. limiting its use to patients who are opioid-tolerant. (correct answer)
  2. requiring the medication to be dispensed in a child-resistant blister pack.
  3. mandating co-prescription of naloxone with every fill.
  4. restricting dispensing to hospital outpatient pharmacies only.
Explanation: A core safety requirement of the TIRF REMS is to ensure these potent immediate-release fentanyl products are only prescribed for and used by patients who are already tolerant to round-the-clock opioid therapy. Use in an opioid-naïve patient could be fatal due to respiratory depression.

Question 2

Who is responsible for developing and proposing a REMS program for a specific medication?

  1. The Food and Drug Administration (FDA)
  2. The Drug Enforcement Administration (DEA)
  3. The medication's manufacturer (correct answer)
  4. The State Board of Pharmacy
Explanation: The manufacturer of the medication is responsible for developing the REMS program. The FDA then reviews and approves the program before the drug can be marketed. The DEA is involved with controlled substances, and State Boards of Pharmacy regulate the practice of pharmacy at the state level.

Question 3

Before dispensing a medication subject to a REMS with Elements to Assure Safe Use (ETASU), what must a pharmacy typically obtain and document?

  1. A patient satisfaction survey score
  2. An authorization number from the REMS program administrator (correct answer)
  3. The lot number of the medication from the previous fill
  4. The patient's primary diagnosis code (ICD-10)
Explanation: For many complex REMS drugs (e.g., isotretinoin, thalidomide), the pharmacy must access the REMS system to verify all requirements are met. The system then provides a specific authorization or confirmation number that permits the pharmacy to dispense the drug and must be documented.

Question 4

A prescription for clozapine is presented at the pharmacy. As part of the Clozapine REMS, what must the pharmacy verify before dispensing?

  1. The patient's current blood pressure reading.
  2. That the patient has no history of smoking.
  3. The patient's most recent Absolute Neutrophil Count (ANC). (correct answer)
  4. That the prescriber has completed a pain management course.
Explanation: The Clozapine REMS program exists to manage the risk of severe neutropenia, a potentially fatal blood condition. Therefore, the pharmacy must verify that the patient has a current Absolute Neutrophil Count (ANC) that is within the acceptable range before each dispensing.

Question 5

While entering a new prescription, a pharmacy technician receives a computer alert stating "REMS DRUG - VERIFY REQUIREMENTS." What is the most appropriate next step for the technician?

  1. Override the alert and continue filling the prescription.
  2. Inform the patient that the drug is not covered by their insurance.
  3. Stop and follow the pharmacy's specific procedures for handling REMS medications. (correct answer)
  4. Tell the prescriber's office that the pharmacy does not carry the medication.
Explanation: A computer alert for a REMS drug is a critical safety warning. The technician must stop the normal workflow and follow the pharmacy's specific policy and procedures for that REMS drug, which may involve checking a website, verifying enrollment, or obtaining an authorization number before proceeding.

Question 6

According to the iPLEDGE REMS program, after receiving an authorization, a pharmacy has a limited time frame to dispense isotretinoin for a female patient of childbearing potential. This "dispensing window" is typically based on the:

  1. date the prescription was written.
  2. date of the patient's negative pregnancy test. (correct answer)
  3. date the patient last saw their dermatologist.
  4. date the pharmacy last ordered the medication.
Explanation: The iPLEDGE dispensing window (typically 7 days) for female patients of childbearing potential starts from the date the specimen was collected for the qualifying negative pregnancy test. The pharmacy must dispense the medication within this window, or a new authorization process must be started.

Question 7

Not all REMS programs are the same. What is the simplest and most common type of REMS requirement?

  1. Patient enrollment in a national registry.
  2. Prescriber certification and special training.
  3. Dispensing the medication with a Medication Guide. (correct answer)
  4. Mandatory inpatient monitoring for the first dose.
Explanation: The most basic level of a REMS program is the requirement to provide a Medication Guide to the patient with each dispensing. More complex programs add on Elements to Assure Safe Use (ETASU), such as patient enrollment, prescriber certification, or specific clinical monitoring.

Question 8

Under the Clozapine REMS program, a patient's prescription can be dispensed if their most recent Absolute Neutrophil Count (ANC) is within the acceptable range. Dispensing is contraindicated if the patient's ANC indicates:

  1. hyperglycemia.
  2. severe neutropenia. (correct answer)
  3. elevated liver enzymes.
  4. high cholesterol.
Explanation: The entire purpose of the Clozapine REMS is to monitor for and prevent clozapine-induced agranulocytosis, which is characterized by severe neutropenia (a dangerously low level of neutrophils). If a patient's ANC falls below the acceptable threshold, dispensing is prohibited to protect the patient.

Question 9

When processing a prescription for a medication with a REMS program, a pharmacy technician's key responsibility might include:

  1. diagnosing the patient's condition to confirm the indication.
  2. verifying the prescriber is certified under the specific REMS program. (correct answer)
  3. recommending an over-the-counter alternative to the patient.
  4. changing the dose based on the patient's reported side effects.
Explanation: A crucial step in the REMS workflow that a technician can perform is verifying that the prescriber and/or pharmacy is certified as required by the program, often through a website or call center. The other actions (diagnosing, recommending OTCs, changing doses) are outside the technician's scope of practice and must be performed by a pharmacist or prescriber.

Question 10

A REMS program can include several components. Which of the following is a potential core component of a comprehensive REMS program?

  1. A patient copay assistance program
  2. Elements to Assure Safe Use (ETASU) (correct answer)
  3. A mandatory generic substitution plan
  4. A direct-to-consumer advertising campaign
Explanation: Elements to Assure Safe Use (ETASU) are a key part of more restrictive REMS programs. They can include requirements like prescriber certification or patient monitoring. The other options are related to marketing or cost-management and are not components of a REMS safety program.

Question 11

The iPLEDGE REMS program is required for dispensing isotretinoin. A key requirement for this program that the pharmacy must verify before dispensing to a female patient of childbearing potential is:

  1. a negative laboratory-based pregnancy test within the last 7 days. (correct answer)
  2. a signed consent form for participation in a clinical trial.
  3. proof of insurance pre-authorization for the medication.
  4. completion of a mandatory 30-day 'washout' period from antibiotics.
Explanation: The iPLEDGE program has a strict requirement for a negative pregnancy test from a CLIA-certified lab within 7 days before dispensing for female patients of childbearing potential. This is a core safety feature to prevent teratogenicity. While insurance pre-authorization may be needed, it is not a REMS requirement.

Question 12

Many REMS programs require that a Medication Guide be dispensed with the prescription. When must the technician ensure a Medication Guide is given to the patient?

  1. Only with the first fill of the prescription.
  2. Only if the patient has a known allergy to a similar medication.
  3. With every dispensing of the medication. (correct answer)
  4. Only when the medication is being used for an off-label indication.
Explanation: When a Medication Guide is a required part of a REMS program, federal law mandates that it be provided to the patient with every dispensing of the medication, including refills, to reinforce the safety information.

Question 13

What is a potential consequence for a pharmacy that repeatedly fails to comply with the requirements of a mandatory REMS program?

  1. The pharmacy may be prohibited from dispensing the REMS medication. (correct answer)
  2. The pharmacy's DEA registration may be immediately revoked.
  3. The pharmacy will be required to pay higher wholesale prices for all drugs.
  4. The pharmacy must switch to a different group purchasing organization (GPO).
Explanation: If a pharmacy does not adhere to the required safety protocols of a REMS program, the manufacturer or the FDA can take action, which may include revoking the pharmacy's certification or ability to obtain and dispense that specific medication. DEA registration is related to controlled substances, not directly to REMS compliance.

Question 14

A REMS program includes a "Communication Plan." What is the main purpose of this component?

  1. To advertise the medication's benefits on television and radio.
  2. To send letters and educational materials about the drug's risks to healthcare providers. (correct answer)
  3. To establish a direct phone line for patients to report side effects to the FDA.
  4. To inform insurance companies about upcoming price changes for the medication.
Explanation: A Communication Plan within a REMS program is designed to educate healthcare providers (including pharmacists, technicians, and prescribers) about the risks associated with the medication and the specific requirements of the REMS program to ensure safe use.

Question 15

A patient asks a technician why they have to sign a special form and get blood work for their medication, but not for their antibiotic. The technician should recognize this is likely due to:

  1. a Drug Supply Chain Security Act (DSCSA) requirement.
  2. a Risk Evaluation and Mitigation Strategy (REMS) program. (correct answer)
  3. a standard requirement for all brand-name medications.
  4. a state-specific prescription drug monitoring program (PDMP).
Explanation: Specific requirements such as patient consent forms, regular lab monitoring (blood work), and certified prescribers or pharmacies are hallmarks of a REMS program with ETASU. DSCSA deals with product tracing. PDMPs track controlled substances. Standard brand-name drugs do not have these requirements unless they are under a REMS.

Question 16

For certain high-risk medications, a REMS program may require patient enrollment. What is the primary reason for this requirement?

  1. To track patient adherence and report it to their insurance company.
  2. To ensure the patient has received education on the risks and agrees to monitoring. (correct answer)
  3. To provide the patient with discount coupons and marketing materials.
  4. To automatically enroll the patient in a recall notification system.
Explanation: Patient enrollment is a mechanism to confirm that the patient has been counseled on the significant risks of the medication and formally agrees to comply with any required safety measures, such as periodic lab tests or pregnancy tests.

Question 17

What is the primary purpose of a Risk Evaluation and Mitigation Strategy (REMS) program as mandated by the FDA?

  1. To ensure the benefits of a medication outweigh its risks. (correct answer)
  2. To track the medication's supply chain from manufacturer to pharmacy.
  3. To report all adverse drug events directly to the manufacturer.
  4. To establish the wholesale acquisition cost for new medications.
Explanation: The primary goal of an FDA-required REMS program is to ensure that a medication's known or potential serious risks do not outweigh its benefits for the patient. The other options describe different programs or concepts. Tracking the supply chain is covered by the DSCSA. Reporting adverse events is done through programs like MedWatch. Establishing cost is a function of the manufacturer and market, not a REMS program.

Question 18

Which of the following is an example of an "Element to Assure Safe Use" (ETASU) that might be required by a REMS program?

  1. The pharmacy must be certified to dispense the medication. (correct answer)
  2. The patient must receive a 90-day supply on the first fill.
  3. The medication must be stored in a locked safe with controlled substances.
  4. The manufacturer must provide free samples to prescribers.
Explanation: Pharmacy certification is a common ETASU, ensuring that the pharmacy understands and can follow the specific dispensing procedures. Dispensing a large initial supply (B) is contrary to the safety goals of most REMS. Storage requirements (C) are typically based on DEA scheduling, not REMS. Samples (D) are a marketing practice.

Question 19

How does processing a prescription for a drug with a complex REMS program, such as one requiring ETASU, typically alter the standard pharmacy workflow?

  1. It requires the technician to compound the medication in a sterile environment.
  2. It adds verification steps that must be completed before the final medication check. (correct answer)
  3. It allows the pharmacy to bypass the drug utilization review (DUR) process.
  4. It shortens the prescription processing time due to pre-authorization.
Explanation: REMS programs add extra steps to the dispensing process. These often include verifying prescriber certification, checking a REMS database for patient authorization, or ensuring lab work is complete. These verification steps must be performed before the pharmacist's final check and will lengthen, not shorten, the overall processing time.

Question 20

A patient has a prescription for a buprenorphine product for opioid use disorder, which is subject to a REMS program. What must the pharmacy ensure before dispensing a refill?

  1. The patient returns their unused medication from the previous fill.
  2. The prescription is a hard copy and not sent electronically.
  3. The patient provides a new government-issued photo ID for each refill.
  4. All REMS requirements are met for each individual fill, not just the first one. (correct answer)
Explanation: Compliance with a REMS program is required for every dispensing, not just the initial fill. The pharmacy must ensure that any required verifications (e.g., prescriber is certified, counseling is offered) are completed for each refill to ensure continued safe use.